Comparative efficacy of indacaterol in chronic obstructive pulmonary disease

International Journal of COPD

Volumn 7, Issue , 2012, Pages 145-152

  Ribeiro, Marcos ^a   Chapman, Kenneth R ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Bronchodilators; Chronic obstructive pulmonary disease; Indacaterol; Long acting 2 agonists; Once daily; Onset of action

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; FORMOTEROL; INDACATEROL; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE;

BLOOD PRESSURE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ECG ABNORMALITY; GENOTOXICITY; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; INHALER; LUNG FUNCTION; MONOTHERAPY; MUSCLE SPASM; POWDER; QT PROLONGATION; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYMPTOM; TACHYCARDIA; TREMOR;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; INDANS; LUNG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; TREATMENT OUTCOME;

EID: 84860282764     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S19805     Document Type: Review

References (33)

1. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370:765-773.
2. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28:523-532.
3. Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax. 2006;61:854-862.
4. GOLD Guidelines. COPD Diagnosis and Management. At-A-Glance Desk Reference. Global Initiative for Chronic Obstructive Pulmonary Disease. Available from: http://www.goldcopd.com. Accessed December 29, 2011.
5. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008;63:831-838.
6. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an Internet survey. Curr Med Res Opin. 2009;25:2043-2048.
7. Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest. 2004;125:249-259.
8. Cazzola M, Matera MG, Lotvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2005;14:775-783.
9. Feldman G, Siler T, Prasad N, et al; INLIGHT 1study group. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a doubleblind, randomised, 12-week study. BMC Pulm Med. 2010;10:11.
10. Calverley PM, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax. 2010;65:719-725.
11. Kerwin EM, Meli J, Henley M, Lassen C, Kramer B. Efficacy and safety of indacaterol 75 μg once daily in patients with moderate to-severe COPD. Am J Respir Crit Care Med. 2011;183:A1595.
12. Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:477-492.
13. Aranson R, Rau JL Jr. The evolution of beta-agonists. Respir Care Clin N Am. 1999:5:479-519.
14. Battram C, Charlton SJ, Cuenoud B, et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1- -hydroxy-ethyl]-8-hydroxy-1H-quino lin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther. 2006;317:762-770.
15. Pearlman DS, Greos L, LaForce C, Orevillo CJ, Owen R, Higgins M. Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma. Ann Allergy Asthma Immunol. 2008;101:90-95.
16. Lombardi D, Cuenoud B, Krämer SD. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties? Eur J Pharm Sci. 2009;38:533-547.
17. EMEA European Medicines Agency. Evaluation of Medicines for Human Use. Assessment Report EMA/659981/2009. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Public_assessment_report/human/001114/WC500053735.pdf. Accessed January 5, 2012.
18. Duvauchelle T, Elharrar B, Knight H, et al. Single-dose indacaterol, a novel 24-hour. 2-agonist, is well tolerated in patients with mild asthma. Eur Respir J. 2005;26 Suppl 49:253s.
19. Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182:155-162.
20. Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily LABA, indacaterol, versus the twice-daily LABA, formoterol, in COPD. Thorax. 2010;65:473-479.
21. Barnes PJ, Pocock SJ, Magnussen H, et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther. 2010;23:165-171.
22. Chapman KR, Rennard SI, Dogra A, Owen R, Lassen C, Kramer B. Long-term safety and efficacy of indacaterol, a long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. 2011;140:68-75.
23. Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo controlled comparison. Eur Respir J. 2011;37:273-279.
24. Laforce C, Aumann J, de Teresa Parreño L, et al. Sustained 24-hour efficacy of once-daily indacaterol (300 mg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study. Pulmon Pharmacol Ther. 2011;24:162-168.
25. Jones PW, Brusselle G, Dal Negro RW, et al. Health-related quality of life in patients by COPD severity within primary care in Europe. Respir Med. 2011;105:57-66.
26. Sears MR. Adverse effects of beta-agonists. J Allergy Clin Immunol. 2002;110:S322-S328.
27. Beier J, Beeh KM, Brookman L, Peachey G, Hmissi A, Pascoe S. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther. 2009;22:492-496.
28. Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ, Plaza Moral V, Schiavi EA. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. Respir Med. 2009;103:1421-1429.
29. Worth H, Chung KF, Felser JM, Hu H, Rueegg P. Cardio-and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med. 2011;105:571-579.
30. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001:23:1296-1310.
31. Barr RG, Celli BR, Mannino DM, et al. Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med. 2009;122:348-355.
32. Cazzola M, Proietto A, Matera MG. Indacaterol for chronic obstructive pulmonary disease (COPD). Drugs Today (Barc). 2010;46:139-150.
33. Chapman KR, Fogarty CM, Peckitt C, et al. Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:353-363.